Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WEE1 | P30291 | 5/20 | 1.00 |
| ▸ | ALK | Q9UM73 | 4/20 | 1.00 |
| ▸ | FLT3 | P36888 | 4/20 | 1.00 |
| ▸ | CDK9 | P50750 | 15/20 | 0.81 |
| ▸ | CDK2 | P24941 | 14/20 | 0.81 |
| ▸ | CDK4 | P11802 | 11/20 | 0.81 |
| ▸ | AURKA | O14965 | 10/20 | 0.81 |
| ▸ | AURKB | Q96GD4 | 10/20 | 0.81 |
| ▸ | CDK7 | P50613 | 11/20 | 0.81 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.81 |
| ▸ | DAPK3 | O43293 | 3/20 | 0.81 |
| ▸ | JAK2 | O60674 | 3/20 | 0.81 |
| ▸ | PRKD3 | O94806 | 3/20 | 0.81 |
| ▸ | PAK4 | O96013 | 3/20 | 0.81 |
| ▸ | ABL1 | P00519 | 3/20 | 0.81 |
| ▸ | FYN | P06241 | 3/20 | 0.81 |
| ▸ | CSF1R | P07333 | 3/20 | 0.81 |
| ▸ | RET | P07949 | 3/20 | 0.81 |
| ▸ | MET | P08581 | 3/20 | 0.81 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4166357 | 0.90 | CDK2 (0.84) | WEE1ALKFLT3CDK9CDK2 | |
| SCHEMBL4158736 | 0.90 | CDK2 (0.82) | WEE1ALKFLT3CDK9CDK2 | |
| SCHEMBL2076207 | 0.90 | CDK2 (1.00) | WEE1ALKFLT3CDK9CDK2 | |
| SCHEMBL4163116 | 0.90 | CDK2 (0.82) | WEE1ALKFLT3CDK9CDK2 | |
| SCHEMBL2076213 | 0.89 | CDK2 (1.00) | WEE1ALKFLT3CDK9CDK2 | |
| SCHEMBL2074623 | 0.87 | CDK2 (0.81) | WEE1ALKFLT3CDK9CDK2 | |
| SCHEMBL4158649 | 0.85 | CDK9 (1.00) | WEE1ALKFLT3CDK9CDK2 | |
| SCHEMBL27684393 | 0.85 | CDK9 (0.77) | WEE1ALKFLT3CDK9CDK2 | |
| SCHEMBL5159297 | 0.85 | CDK2 (0.75) | WEE1ALKFLT3CDK9CDK2 | |
| SCHEMBL4167442 | 0.84 | CDK2 (0.80) | WEE1ALKFLT3CDK9CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137572-A1 | 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders | CYCLACEL LIMITED (GB) | 2009-05-28 | — | — | US | claimed |
| WO-2007132228-A1 | COMBINATION OF CNDAC WITH A 2-SUBSTITUTED-4-HETER0ARYL-PYRIMIDINE AMINE AND USE THEREOF IN THE TREATMENT OF A PROLIFERATIVE DISORDER | CYCLACEL LIMITED (GB) | 2007-11-22 | — | — | WO | claimed |
| WO-2007132221-A1 | COMBINED ANTICANCER PYRIMIDINE-THIAZOLE AURORA KINASE INHIBITORS | CYCLACEL LIMITED (GB) | 2007-11-22 | — | — | WO | claimed |
| WO-2007132220-A1 | COMBINATION OF A 2-SUBSTITUTED-4-HETER0ARYL-PYRIMIDINE AMINE WITH A CYTOTOXIC DRUG AND USE THEREOF IN THE TREATMENT OF A PROLIFERATIVE DISORDER | CYCLACEL LIMITED (GB) | 2007-11-22 | — | — | WO | claimed |
| EP-1756098-A2 | 2-SUBSTITUTED-4-HETEROARYL-PYRIMIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | Cyclacel Limited (GB) | 2007-02-28 | — | — | EP | claimed |
| WO-2005116025-A2 | 2-SUBSTITUTED-4-HETEROARYL-PYRIMIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | CYCLACEL LIMITED (GB) | 2005-12-08 | — | — | WO | claimed |
| US-20090137572-A1 | 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders | CYCLACEL LIMITED (GB) | 2009-05-28 | — | — | US | disclosed |
| US-20090137572-A1 | 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders | CYCLACEL LIMITED (GB) | 2009-05-28 | — | — | US | disclosed |
| US-20090137572-A1 | 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders | CYCLACEL LIMITED (GB) | 2009-05-28 | — | — | US | disclosed |
| WO-2007132228-A1 | COMBINATION OF CNDAC WITH A 2-SUBSTITUTED-4-HETER0ARYL-PYRIMIDINE AMINE AND USE THEREOF IN THE TREATMENT OF A PROLIFERATIVE DISORDER | CYCLACEL LIMITED (GB) | 2007-11-22 | — | — | WO | disclosed |
| WO-2007132228-A1 | COMBINATION OF CNDAC WITH A 2-SUBSTITUTED-4-HETER0ARYL-PYRIMIDINE AMINE AND USE THEREOF IN THE TREATMENT OF A PROLIFERATIVE DISORDER | CYCLACEL LIMITED (GB) | 2007-11-22 | — | — | WO | disclosed |
| WO-2007132221-A1 | COMBINED ANTICANCER PYRIMIDINE-THIAZOLE AURORA KINASE INHIBITORS | CYCLACEL LIMITED (GB) | 2007-11-22 | — | — | WO | disclosed |
| WO-2007132221-A1 | COMBINED ANTICANCER PYRIMIDINE-THIAZOLE AURORA KINASE INHIBITORS | CYCLACEL LIMITED (GB) | 2007-11-22 | — | — | WO | disclosed |
| WO-2007132220-A1 | COMBINATION OF A 2-SUBSTITUTED-4-HETER0ARYL-PYRIMIDINE AMINE WITH A CYTOTOXIC DRUG AND USE THEREOF IN THE TREATMENT OF A PROLIFERATIVE DISORDER | CYCLACEL LIMITED (GB) | 2007-11-22 | — | — | WO | disclosed |
| WO-2007132220-A1 | COMBINATION OF A 2-SUBSTITUTED-4-HETER0ARYL-PYRIMIDINE AMINE WITH A CYTOTOXIC DRUG AND USE THEREOF IN THE TREATMENT OF A PROLIFERATIVE DISORDER | CYCLACEL LIMITED (GB) | 2007-11-22 | — | — | WO | disclosed |
| EP-1756098-A2 | 2-SUBSTITUTED-4-HETEROARYL-PYRIMIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | Cyclacel Limited (GB) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005116025-A2 | 2-SUBSTITUTED-4-HETEROARYL-PYRIMIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | CYCLACEL LIMITED (GB) | 2005-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137572-A1 | 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders | CDK2, CDK4, CDK20 | WEE1 185/4885ALK 1366/4885FLT3 618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.